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ABSTRACT 
Improving oral bioavailability of low poorly water soluble drugs using 
self-emulsifying drug delivery systems (SEDDS) possess significant 
potential. Oral bioavailability of hydrophobic drugs can be improved 
using SEDDS, and appears most promising. Their dispersion in gastro 
intestinal (GI) fluid after administration forms micro or nano emulsified 
drug which gets easily absorbed through lymphatic pathways bypassing 
the hepatic first pass metabolism. Parameters like surfactant concentration, 
oil to surfactant ratio, polarity of emulsion, droplet size and charge on 
droplet plays a critical role in oral absorption of drug from SEDDS. For 
hydrophobic drug substances that exhibit dissolution step as rate limiting 
for absorption, SEDDS offer an improvement in rate and extent of 
absorption and gives more reproducible plasma concentration time 
profiles. Use of combined in vitro dispersion and digestion methodologies 
has enabled a much improved understanding of role of intestinal lipid 
processing on solubilization behavior of lipid based drug delivery systems 
(LBDDS). The article gives a brief view on the solid lipid nanoparticles 
and its evaluation. 
Keywords: Self-Emulsifying formulation, Lipid-based drug delivery systems, 
Characterization, Bioavailability enhancement 
 
Introduction 
Self emulsifying drug delivery system (SEDDS) 
is defined as isotropic mixture of oil and 
surfactants or alternatively one or more 
hydrophilic solvents and co-solvents. Upon mild 
agitation followed by dilution in aqueous media 
such as the gastrointestinal (GI) fluid, these 
systems can form fine oil in water (o/w) 
emulsions or micro emulsions. Self micro 
emulsifying formulations spread readily in the 
GI tract and the digestive motility of the 
stomach and the intestine provide the agitation 
necessary for self-emulsification (SEDDS) 
typically produce emulsion with a droplet size 
between 100 and 300 nm while SMEDDS form 
transparent micro emulsion with a droplet size of 
less than 50 nm. When compared with 
emulsions which are sensitive and metastable 
dispersed forms, SEDDS and SMEDDS are 
physically stable formulations that are easy to 
manufacture. SMEDDS can be formulated to 
give sustained release dosage form by adding 
polymeric matrix, which is not ionizable at 
physiological pH and after ingestion in contact 
with GI fluid forms a gelled polymer making it 
possible to release the micro emulsified active 
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agent in a continuous and sustained matter by 
diffusion. Bases of self micro emulsifying 
system have been formulated using medium 
chain triglyceride oils and non-ionic surfactant 
which are acceptable for oral ingestion. The 
lipophilic (poorly water soluble) drugs such as 
nifedipine, griseofulvin, cyclosporine, digoxin, 
itrconazole, carbamazepine, piroxicam, steroids, 
ibuprofen, diazepam, etc. are formulated in 
SMEDDS to improve efficacy and safety. It 
should be noted that water-in-oil version of 
SMEDDS has also been investigated. This 
system can be liquid but also semisolid 
depending on the excipient’s choice. These are 
traditionally designed for the oral route. These 
preparations can be given as soft or hard gelatin 
capsules for easy administration and precise 
dosage.  
The better absorbed drugs across the 
gastrointestinal tract (GIT) provide good oral 
bioavailability but have number of potentially 
limiting factors. These include appropriate 
stability and solubility in the GI fluid, 
reasonable intestinal permeability, and resistance 
to metabolism both within the enterocyte and the 
liver.1 It has realized that the oral bioavailability 
of poorly water soluble, lipophilic drugs may be 
enhanced when coadministered with a meal rich 
in fat this has led to increase recent interest in 
the formulation of poorly soluble drugs in lipids 
as a means to enhance drug solubilisation in the 
GIT.2-7 Lipid-based formulations not only 
improve but normalize drug absorption, which is 
particularly beneficial for low therapeutic index 
drugs.8-10 These formulations can also enhance 
drug absorption by a number of ancillary 
mechanisms, e.g. (a) including inhibition of P-
glycoprotein-mediated drug efflux and pre 
absorptive metabolism by gut membrane-bound 
cytochrome enzymes (b) promotion of lymphatic 
transport, which delivers drug directly to the 
systemic circulation while avoiding hepatic first-
pass metabolism and (c) by increasing GI 
membrane permeability.11-15 Modification of the 
physicochemical properties, such as salt 
formation and particle size reduction of the 
compound may be one approach to improve the 
dissolution rate of the drugs.16,17 However, these 
methods have their own limitations. In recent 
years much attention has focused on lipid−based 
formulations to improve the oral bioavailability 
of poorly soluble drugs .In fact, the most popular 
approach is the incorporation of the drug 
compound into inert lipid vehicles such as oils, 
surfactant dispersions, self-emulsifying 
formulations, emulsions and liposomes with 
particular emphasis on self-emulsifying drug 
delivery systems (SEDDS). 
Novelty statement 
This review on Self Emulsifying Drug Delivery 
Systems (SEDDS) is written as these drug 
delivery systems have unparalleled prospect in 
enhancing bioavailability of low soluble drugs 
of biopharmaceutical classification. An 
extensive and updated description of literature 
reports on different types of self emulsifying 
formulations, techniques employed, 
characterization, optimization and application 
strategies are discussed comprehensively to 
direct the formulation scientists in formulating a 
stable, safe and effective self emulsifying 
formulation. The figures are self designed to 
prove the concept, mechanism and meaning of 
SEDDS. 
Self-emulsifying drug delivery 
systems (SEDDS) 
SEDDS belong to lipid-based formulations. 
Lipid formulations can be oils, surfactant 
dispersions, emulsions, solid lipid nanoparticles 
and liposomes. SEDDS are isotropic mixtures of 
drug, lipids and surfactants, usually with one or 
more hydrophilic co-solvents or co-emulsifiers. 
Upon mild agitation followed by dilution with 
aqueous media, these systems can form fine (oil 
in water) emulsion instantaneously. ‘SEDDS’ is 
a broad term, typically producing emulsions 
with a droplet size ranging from a few 
nanometers to several-microns. “Self micro- 
emulsifying drug delivery systems” (SMEDDS) 
indicates the formulations forming transparent 
microemulsions with oil droplets ranging 
between 100 and 250 nm. “Self-nano-
emulsifying drug delivery systems” (SNEDDS) 
is a recent term with the globule size ranges less 
than 100 nm.18 A schematic about self-micro-
emulsifying drug delivery systems” (SMEDDS) 
is shown in Figure 1.  
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Figure 1: Illustration of what is SEDDS. 
It has been suggested that self-emulsifying drug 
delivery systems can be prepared which, after 
oral administration in gelatin capsules, will 
emulsify within the gastric contents.19 
Advantage of self-emulsifying formulations over 
solid dosage formulations is the avoidance of 
slow drug dissolution. Distribution of the 
emulsion within the GIT helps to avoid the 
irritancy. Some marketed self emulsified dosage 
forms are described in Table 1. 
Table 1: Marketed self emulsified dosage 
forms. 
Drug 
name 
Compou
nd 
Dosage 
form 
Company 
Neoral Cyclosp
orin 
Soft gelatin 
capsules 
Novartis 
Norvir Ritonavi
r 
Soft gelatin 
capsules 
Abott 
laboratori
es 
Fortavas
e 
Saquinav
ir 
Soft gelatin 
capsules 
Hoffmann
-LaRoche 
Inc. 
Agenera
se 
Amprena
vir 
Soft gelatin 
capsules 
Glaxosmit
hkline 
Solufen Ibuprofe
n 
Hard 
gelatin 
capsules 
Sanofi-
Aventis 
Solufen Fenofibr
ate 
Hard 
gelatin 
capsules 
Sanofi-
Aventis 
 
Need of SEDDS 
Oral delivery of poorly water-soluble 
compounds is to pre-dissolve the compound in a 
suitable solvent and fill the formulation into 
capsules. The main benefit of this approach is 
that predissolving the compound overcomes the 
initial rate limiting step of particulate dissolution 
in the aqueous environment within the GI tract. 
However, a potential problem is that the drug 
may precipitate out of solution when the 
formulation disperses in the GI tract, particularly 
if a hydrophilic solvent is used (e.g. 
polyethylene glycol). If the drug can be 
dissolved in a lipid vehicle there is less potential 
for precipitation on dilution in the GI tract, as 
partitioning kinetics will favor the drug 
remaining in the lipid droplets. Another strategy 
for poorly soluble drugs is to formulate in a solid 
solution using a water-soluble polymer to aid 
solubility of the drug compound. For example, 
polyvinyl pyrrolidone (PVP) and polyethylene 
glycol (PEG 6000) have been used for preparing 
solid solutions with poorly soluble drugs. One 
potential problem with this type of formulation 
is that the drug may favor a more 
thermodynamically stable state, which can result 
in the compound crystallizing in the polymer 
matrix. Therefore the physical stability of such 
formulations needs to be assessed using 
techniques such as differential scanning 
calorimetry or X-ray crystallography. In this 
type of case SEDD system is a good option.20-22 
 
Figure 2: Potential advantages of these 
systems. 
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Limitations of SEDDS 
 Chemical instabilities of drug and high 
surfactant concentrations 
 The large amount of surfactant in self-
emulsifying formulations (30-60%) irritates 
GIT 
 Moreover, volatile co-solvent in the 
conventional self-emulsifying formulations 
are known to migrate into the shells of soft 
or hard gelatin capsule, resulting in the 
precipitation of the lipophilic drug.23 
Mechanism of SEDDS 
Different approaches have been reported in the 
literature. No single theory explains all aspects 
of micro emulsion formation. Schulman et al. 
considered that the spontaneous formation of 
micro emulsion droplets was due to the 
formation of a complex film at the oil‐water 
interface by the surfactant and co‐surfactant. 
Thermodynamic theory of formation of micro 
emulsion explains that emulsification occurs, 
when the entropy change that favour dispersion 
is greater than the energy required to increase 
the surface area of the dispersion and the free 
energy (ΔG) is negative. The free energy in the 
micro emulsion formation is a direct function of 
the energy required to create a new surface 
between the two phases and can be described by 
the equation: 
ΔG = Σ Nᴫ r2 σ 
Where, ΔG is the free energy associated with the 
process (ignoring the free energy of the mixing). 
N is the number of droplets of radius r and σ are 
presents the interfacial energy. With time, the 
two phases of the emulsion tend to separate to 
reduce the interfacial area, and subsequently, the 
free energy of the system decreases. Therefore, 
the emulsion resulting from aqueous dilution are 
stabilized by conventional emulsifying agents, 
which forms a mono layer around the emulsion 
droplets, and hence, reduce the interfacial 
energy, as well as providing a barrier to prevent 
coalescence.24 
 
Lipid formulation classification 
system (LFCS) 
LFCS was established by Pouton in 2000 and 
recently updated (2006) to help stratify 
formulations into those with similar component 
parts.25 The LFCS briefly classifies lipid-based 
formulations into four types according to their 
composition and the possible effect of dilution 
and digestion on their ability to prevent drug 
precipitation. A schematic illustration on lipid 
formulation classification system is given in 
Table 2. 
Type I lipid formulations 
It consist of formulations which comprise drug 
in solution in triglycerides and/or mixed 
glycerides or in an oil in water emulsion 
stabilized by low concentrations of emulsifiers 
such as 1% (w/v) polysorbate 60 and 1.2% (w/v) 
lecithin.26 Generally, these systems exhibit poor 
initial aqueous dispersion and require digestion 
by pancreatic lipase/ co-lipase in the GIT to 
generate more amphiphilic lipid digestion 
products and promote drug transfer into the 
colloidal aqueous phase. Type I lipid 
formulations therefore represent a relatively 
simple formulation option for potent drugs or 
highly lipophilic compounds where drug 
solubility in oil is sufficient to allow 
incorporation of the required payload (dose).27 
Type II lipid formulations 
Self-emulsification is generally obtained at 
surfactant contents above 25% (w/w). However, 
at higher surfactant contents (greater than 50–
60% (w/w) depending on the materials) the 
progress of emulsification may be compromised 
by the formation of viscous liquid crystalline 
gels at the oil/water interface.28,29 Type II lipid-
based formulations provide the advantage of 
overcoming the slow dissolution step typically 
observed with solid dosage forms and as 
described above generate large interfacial areas 
which in turn allows efficient partitioning of 
drug between the oil droplets and the aqueous 
phase from where absorption occurs.30,31 
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Table 2: Lipid formulation classification system (LFCS) as described by Pouton showing typical 
compositions and properties of lipid based formulations. 
Composition Type I 
OIL 
Type II 
SEDDS 
Type III A 
SEDDS 
Type III B 
SMEDDS 
Type IV 
OIL- Free 
Glycerides(TG,DG, 
MG) 
 
Water insoluble 
Surfactants(HLB 
<12) 
 
Water soluble 
surfactants(HLB > 
12)  
 
Hydrophilic co-
solvents 
 
Particle size of 
dispersion(nm) 
 
Significance of 
aqueous Dilution 
 
 
 
Significance of 
digestibility 
 
 
100% 
 
 
 
- 
 
- 
 
 
        - 
 
 
Coarse 
 
 
Ltd. 
importance 
 
 
 
Crucial 
need 
40-80% 
 
 
 
20-60% 
 
20-40% 
 
 
- 
 
 
100-250 
 
 
Solvent 
capacity 
unaffected 
 
 
Not crucial 
but likely to 
occur 
 
40-80% 
 
 
 
- 
 
- 
 
 
0-40% 
 
 
100-250 
 
 
Some loss of 
solvent 
capacity 
 
 
Not crucial 
but 
may be 
inhibited 
< 20% 
 
 
 
- 
 
20-50% 
 
 
20-50% 
 
 
50-100 
 
 
Significant 
phase changes 
and potential 
loss of solvent 
capacity 
Not required 
- 
 
 
 
0-20% 
 
20-80% 
 
 
0-80% 
 
 
< 50 
 
 
Significant 
phase 
changes and 
potential loss of 
solvent capacity 
Not required 
 
 
 
Type III lipid formulation 
Commonly referred to as self-microemulsifying 
drug delivery systems (SMEDDS), are defined 
by the inclusion of hydrophilic surfactants 
(HLB>12) and co-solvents such as ethanol, 
propylene glycol and polyethylene glycol. Type 
III formulations can be further segregated 
(somewhat arbitrarily) into Type IIIA and Type 
IIIB formulations in order to identify more 
hydrophilic systems (Type IIIB) where the 
content of hydrophilic surfactants and co-
solvents increases and the lipid content reduces. 
Type IIIB formulations typically achieve greater 
dispersion rates when compared with Type IIIA 
although the risk of drug precipitation on 
dispersion of the formulation is higher given the 
lower lipid content. 
Type IV lipid formulation 
In order to capture the recent trend towards 
formulations which contain predominantly 
hydrophilic surfactants and cosolvents, this 
category was recently added.25Type IV 
formulations do not contain natural lipids and 
represent the most hydrophilic formulations. 
These formulations commonly offer increased 
drug payloads when compared to formulations 
containing simple glyceride lipids and also 
produce very fine dispersions when introduced 
in aqueous media. Little is known however, as to 
the solubilisation capacity of these systems in 
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vivo and in particular whether they are equally 
capable of maintaining poorly water soluble 
drug in solution during passage along the GIT 
when compared with formulations comprising 
natural oils (Type II and Type III). An example 
of a Type IV formulation is the current capsule 
formulation of the HIV protease inhibitor 
amprenavir (Agenerase) which contains TPGS 
as a surfactant and PEG 400 and propylene 
glycol as co-solvents.32 
Excipients used in SMEDDS 
Pharmaceutical acceptability of excipients and 
the toxicity issues of the components used 
makes the selection of excipients really critical. 
There is a great restriction as which excipients to 
be used. Early studies revealed that the self-
microemulsification process is specific to the 
nature of the oil/surfactant pair, the surfactant 
concentration and oil/surfactant ratio, the 
concentration and nature of co-surfactant and 
surfactant/co-surfactant ratio and the 
temperature at which self-microemulsification 
occurs. These important discoveries were further 
supported by the fact that only very specific 
combinations of pharmaceutical excipients led to 
efficient self- microemulsifying systems. 
Oils 
The oil represents one of the most important 
excipients in the SMEDDS formulation not only 
because it can solubilize the required dose of the 
lipophilic drug or facilitate self emulsification 
but also and mainly because it can increase the 
fraction of lipophilic drug transported via the 
intestinal lymphatic system, thereby increasing 
absorption from the GI tract depending on the 
molecular nature of the triglyceride.33 Both long 
and medium chain triglyceride (LCT and MCT) 
oils with different degrees of saturation have 
been used for the design of self-emulsifying 
formulations. Furthermore, edible oils which 
could represent the logical and preferred lipid 
excipients choice for the development of 
SMEDDS are not frequently selected due to 
their poor ability to dissolve large amounts of 
lipophilic drugs. Modified or hydrolyzed 
vegetable oils have been widely used since these 
excipients form good emulsification systems 
with a large number of surfactants approved for 
oral administration and exhibit better drug 
solubility properties.34 They offer formulative 
and physiological advantages and their 
degradation products resemble the natural end 
products of intestinal digestion. Novel 
semisynthetic medium chain derivatives, which 
can be defined as amphiphilic compounds with 
surfactant properties, are progressively and 
effectively replacing the regular medium chain 
triglyceride oils in the SMEDDS.35 This is in 
accordance with findings of Deckelbaum (1990) 
showing that MCT is more soluble and have a 
higher mobility in the lipid/water interfaces than 
LCT associated with a more rapid hydrolysis of 
MCT. In general, when using LCT, a higher 
concentration of cremophor RH40 was required 
to form microemulsions compared with MCT. 
E.g.: Cotton seed oil, Soybean oil, Corn oil, 
Sunflower oil, Castor oil etc. 
Surfactants 
Several compounds exhibiting surfactant 
properties may be employed for the design of 
self-emulsifying systems, but the choice is 
limited as very few surfactants are orally 
acceptable. The most widely recommended ones 
being the non-ionic surfactants with a relatively 
high hydrophilic-lipophilic balance (HLB). The 
commonly used emulsifiers are various solid or 
liquid ethoxylated polyglycolyzed glycerides 
and polyoxyethylene oleate. Safety is a major 
determining factor in choosing a surfactant. 
Emulsifiers of natural origin are preferred since 
they are considered to be safer than the synthetic 
surfactants.36 However, these surfactants have a 
limited self-emulsification capacity. Non-ionic 
surfactants are less toxic than ionic surfactants 
but they may lead to reversible changes in the 
permeability of the intestinal lumen.37 The lipid 
mixtures with higher surfactant and co-
surfactant/oil ratios lead to the formation of 
SMEDDS. 
There is a relationship between the droplet size 
and the concentration of the surfactant being 
used. In some cases, increasing the surfactant 
concentration could lead to droplets with smaller 
mean droplet size, this could be explained by the 
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stabilization of the oil droplets as a result of the 
localization of the surfactant molecules at the 
oil-water interface.38 On the other hand, in some 
cases the mean droplet size may increase with 
increasing surfactant concentrations.39 This 
phenomenon could be attributed to the 
interfacial disruption elicited by enhanced water 
penetration into the oil droplets mediated by the 
increased surfactant concentration and leading to 
ejection of oil droplets into the aqueous phase.40 
The surfactants used in these formulations are 
known to improve the bioavailability by various 
mechanisms including: improved drug 
dissolution, increased intestinal epithelial 
permeability, increased tight junction 
permeability and decreased/inhibited 
pglycoprotein drug efflux. However, the large 
quantity of surfactant may cause moderate 
reversible changes in intestinal wall permeability 
or may irritate the GI tract. Formulation effect 
and surfactant concentration on gastrointestinal 
mucosa should ideally be investigated in each 
case. 
 Surfactant molecules may be classified based on 
the nature of the hydrophilic group within the 
molecule. The four main groups of surfactants 
are defined as follows, 
1. Anionic surfactants 
2. Cationic surfactants 
3. Ampholytic surfactants 
4. Nonionic surfactants 
Anionic Surfactants: where the hydrophilic 
group carries a negative charge such as carboxyl 
(RCOO-), sulphonate (RSO3-) or sulphate 
(ROSO3-). Examples: Potassium laurate, 
sodium lauryl sulphate. 
Cationic surfactants: where the hydrophilic 
group carries a positive charge. Example: 
quaternary ammonium halide. 
Ampholytic surfactants: (also called zwitter 
ionic surfactants) contain both a negative and a 
positive charge. Example: sulfobetaines. 
Nonionic surfactants: where the hydrophilic 
group carries no charge but derives its water 
solubility from highly polar groups such as 
hydroxyl or polyoxyethylene (OCH2CH2O). 
Examples: Sorbitan esters (Spans), polysorbates 
(Tweens).  
Co-solvents 
The production of an optimum SEDDS requires 
relatively high concentrations (generally more 
than 30% w/w) of surfactants, thus the 
concentration of surfactant can be reduced by 
incorporation of co surfactant. Role of the co-
surfactant together with the surfactant is to lower 
the interfacial tension to a very small even 
transient negative value. At this value the 
interface would expand to form fine dispersed 
droplets, and subsequently adsorb more 
surfactant and surfactant/co-surfactant until their 
bulk condition is depleted enough to make 
interfacial tension positive again. This process 
known as 'spontaneous emulsification' forms the 
microemulsion. However, the use of co-
surfactant in self emulsifying systems is not 
mandatory for many non-ionic surfactants. The 
selection of surfactant and co-surfactant is 
crucial not only to the formation of SEDDS, but 
also to solubilization of the drug in the SEDDS. 
Organic solvents, suitable for oral administration 
(ethanol, propylene glycol (PG), polyethylene 
glycol (PEG), etc.) may help to dissolve large 
amounts of either the hydrophilic surfactant or 
the drug in the lipid base and can act as co-
surfactant in the self emulsifying drug delivery 
systems, although alcohol- free self-emulsifying 
microemulsions have also been described in the 
literature. Indeed, such systems may exhibit 
some advantages over the previous formulations 
when incorporated in capsule dosage forms, 
since alcohol and other volatile co-solvents in 
the conventional self-emulsifying formulations 
are known to migrate into the shells of soft 
gelatin or hard sealed gelatin capsules resulting 
in the precipitation of the lipophilic drug. On the 
other hand, the lipophilic drug dissolution ability 
of the alcohol free formulation may be limited. 
Hence, proper choice has to be made during 
selection of components.41 
 Co-surfactant 
In SMEDDS, generally co-surfactant of HLB 
value 10-14 is used. Hydrophilic co-surfactants 
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are preferably alcohols of intermediate chain 
length such as hexanol, pentanol and octanol 
which are known to reduce the oil water 
interface and allow the spontaneous formulation 
of micro emulsion. E.g. span, capyrol 90, 
capmul.42,43  
Recent dosage form development in 
SEDDS  
1. Dry emulsions 
2. Self- emulsifying capsules 
3. Self- emulsifying sustained/controlled-release 
tablets 
4. Self- emulsifying sustained/controlled-release 
pellets 
5. Self emulsifying solid dispersions 
6. Self emulsifying beads 
7. Self emulsifying Sustained release 
microspheres 
8. Self-emulsifying nanoparticles 
9. Self-emulsifying suppositories 
10. Self emulsifying implants.44-51 
Drug properties suitable for 
SEDDS 
1. Dose should not be so high 
2. Drug should be oil soluble 
3. High melting point drug is poorly suited to 
sedds 
4. Log P Value should be high. 
Characterization of SEDDS 
The very essence of SEDDS is self-
emulsification, which is primarily assessed 
visually. The various ways to characterize 
SEDDS are compiled below. 
1. Equilibrium phase diagram: Although self 
emulsification is a dynamic non equilibrium 
process involving interfacial phenomena, 
information can be obtained about self-
emulsification using equilibrium phase 
behavior. 
2. Turbidity measurement: This identifies 
efficient self-emulsification by establishing 
whether the dispersion reaches equilibrium 
rapidly and in a reproducible time. These 
measurements are carried out on turbidity 
meters, most commonly the Hach turbidity 
meter and the Orbeco-Helle turbidity meter. 
3. Droplet size: This is a crucial factor in self-
emulsification performance because it 
determines the rate and extent of drug 
release, as well as the stability of the 
emulsion. Photon correlation spectroscopy, 
microscopic techniques or a Coulter Nano-
sizer are mainly used for the determination 
of the emulsion droplet size. Electron 
microscopic studies: Freeze-fracture 
electron microscopy has been used to study 
surface characteristics of dispersed systems. 
4. Zeta potential measurement: This is used to 
identify the charge of the droplets. In 
conventional SEDDS, the charge on an oil 
droplet is negative because of the presence 
of free fatty acids.  
5. Determination of emulsification time: The 
process of self-emulsification was observed 
using light microscopy. The mechanism of 
emulsification involved erosion of a fine 
cloud of small particles from the surface of 
large droplets, rather than a progressive 
reduction in droplet size. 
6. Liquefaction time: This test is designed to 
estimate the time required by solid SEDDS 
to melt in vivo in the absence of agitation to 
simulated GI conditions. 
7. Small-angle neutron scattering: Small-angle 
neutron scattering can be used to obtain 
information on the size and shape of the 
droplets. 
8. Small-angle X-ray scattering: Small-angle 
X-ray scattering is capable of delivering 
structural information of macromolecules 
between 5 and 25 nm, of repeat distances in 
partially ordered systems of up to 150 nm. It 
is used for the determination of the 
microscale or nanoscale structure of particle 
systems in terms of such parameters as 
averaged particle sizes, shapes, distribution 
and surface-to-volume ratio.52-59 
Solid self-emulsifying drug delivery 
system (S-SEDDS) 
S-SEDDS mean solid dosage forms with self-
emulsification properties. S-SEDDS focus on 
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the incorporation of liquid/semisolid SE 
ingredients into powders/nanoparticles by 
different solidification techniques (e.g. 
adsorptions to solid carriers, spray drying, melt 
extrusion, nano-particle technology). 
In the 1990s, S-SEDDS were usually in the form 
of SE capsules, SE solid dispersions and dry 
Emulsions, but other solid SE dosage forms 
have emerged in recent years, such as SE 
pellets/tablets, SE microspheres/nanoparticles 
and SE suppositories/implants. SEDDS are 
usually, however, limited to liquid dosage forms, 
because many excipients used in SEDDS are not 
solids at room temperature. 
Solidification techniques for 
transforming liquid / semisolid 
SEDDS to solid SEDDS 
Capsule filling with liquid and semisolid self-
emulsifying formulations 
Capsule filling is the simplest and the most 
common technology for the encapsulation of 
liquid or semisolid SE formulations for the oral 
route. In parallel with the advances in capsule 
technology proceeding, liquid-Oros technology 
(Alza Corporation) has been designed for 
controlled delivery of insoluble drug substances 
or peptides. This system is based on osmotic 
principles and is a liquid SE formulation system. 
It consists of an osmotic layer, which expands 
after coming into contact with water and pumps 
the drug formulation through an orifice in the 
hard or soft capsule. A primary consideration in 
capsule filling is the compatibility of the 
excipients with the capsule shell. The 
liquid/semisolid lipophilic vehicles compatible 
with hard capsules were listed by.60 The 
advantages of capsule filling are simplicity of 
manufacturing, suitability for low dose highly 
potent drugs and high drug loading (up to 50% 
(w/w) potential. 
Spray drying 
This technique involves the preparation of a 
formulation by mixing lipids, surfactants, drug, 
solid carriers, and solubilization of the mixture 
before spray drying. The solubilized liquid 
formulation is then atomized into a spray of 
droplets. The droplets are introduced into a 
drying chamber, where the volatile phase (e.g. 
the water contained in an emulsion) evaporates, 
forming dry particles under controlled 
temperature and airflow conditions. Such 
particles can be further prepared into tablets or 
capsules. 
Spray cooling 
Spray cooling also referred to as spray 
congealing is a process whereby the molten 
formula is sprayed into a cooling chamber. Upon 
contact with the cooling air, the molten droplets 
congeal and re-crystallize into spherical solid 
particles that fall to the bottom of the chamber 
and subsequently collected as fine powder. The 
fine powder may then be used for development 
of solid dosage forms, tablets or direct filling 
into hard shell capsules. Many types of 
equipment are available to atomize the liquid 
mixture and to generate droplets: rotary 
pressure, two-fluid or ultrasonic atomizers.60, 61 
Adsorption to solid carriers 
SEDDS can be adsorbed at high levels (up to 
70% (w/w)) onto suitable carriers. Solid carriers 
can be microporous inorganic substances, high 
surface area colloidal inorganic adsorbent 
substances, cross-linked polymers or 
nanoparticle adsorbents (e.g., silica, silicates, 
magnesium trisilicate, magnesium hydroxide, 
talcum, crospovidone, cross-linked sodium 
carboxymethyl cellulose and cross-linked 
polymethyl methacrylate). The adsorption 
technique has been successfully applied to 
gentamicin and erythropoietin with 
caprylocaproyl polyoxylglycerides (Labrasol) 
formulations that maintained their 
bioavailability enhancing effect after adsorption 
on carriers.62-64 
Melt granulation 
Melt granulation or pelletization is a one step-
process allowing the transformation of a powder 
mix (containing the drug) into granules or 
spheronized pellets. The technique needs high 
shear mixing in presence of a meltable binder. 
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This is referred to as “pump-on” technique. 
Alternatively, the binder may be blended with 
the powder mix in its solid or semi-solid state 
and allowed to melt (partially or completely) by 
the heat generated from the friction of particles 
during high shear mixing referred to as “melt-in” 
process. The melted binder forms liquid bridges 
with the powder particles that shape into small 
agglomerates (granules) which can, by further 
mixing under controlled conditions transform to 
spheronized pellets.65-67 
Melt extrusion/extrusion spheronization 
It is a solvent-free process that allows high drug 
loading (60%) as well as content uniformity. 
Applying extrusion-spheronization, SE pellets of 
diazepam and progesterone and bi-layered 
cohesive SE pellets have been prepared.68,69 
Bioavailability enhancement 
Oral drug bioavailability of a chemically stable 
drug is limited by its solubility and its 
permeability. Poor drug absorption therefore can 
be caused by inadequate rate and extent of drug 
dissolution and or low permeation. Accordingly 
as per the biopharmaceutical classification 
system, a drug on the basis of these solubility 
Table 3: Literature updates on various reports of bioavailability enhancement using self-emulsifying 
formulations. 
Drug Enhancement With reference to Species 
Acyclovir 3.5 fold Pure drug solution Male albino rats 
Anethole trithione 2.5 fold Tablets Rabbits 
Atorvastatin 1.5 fold Conventional tablet Beagle dogs 
Bicalutamide 2 fold Suspension Rats 
Carvedilol 4.13 fold Commercial tablet Beagle dogs 
Carvedilol 1.56 fold Luode (a commercial tablet) Beagle dogs 
Danazold 2 fold Pure surfactant solution Beagle dogs 
Fenofibrate 1.075 fold Tricor tablets Human 
Gentamycin 5 fold I.V saline Beagle dogs 
Insulin 1.15 fold Subcutaneous injection Beagle dogs 
Itraconazole 1.9-2.5 fold Sporanox capsules Humans 
Itraconazole 2 fold Solid dispersion Rats 
Ketoconazole 2 fold Pure drug Rats 
Ketoprofen 1.13 fold Pure drug Humans 
Mitotane 3.4 fold Lysodren Rabbits 
Nimodipine 2.6-6.6 fold Conventional tablet New Zealand 
Male rabbits 
Nimodipine 4.6 fold 
1.91 fold 
1.53 fold 
Suspension 
Oily solution 
Micellar solution 
Male rabbits 
Nitrendipine 1.6 fold Conventional tablet Beagle dogs 
Silymarin 3.6 fold Legalon capsule Rats 
Oleanolic acid 2.4 fold Tablet Rats 
Simvastatin 1.5 fold Zocor tablets Beagle dogs 
Tretinoin 1.67 fold Commercial capsule formulation Beagle dogs 
 
Thakare P. et al. Pharmaceutical and Biological Evaluations 2016; vol. 3 (2): 140-153. 
150 
 
©Pharmaceutical and Biological Evaluations 
 
and permeability characteristics classified in to 
four possible categories, class I to IV. 
Bioavailability of poorly soluble class II drugs, 
on the contrary is dependent on their aqueous 
solubility/ dissolution rate. As these drugs tend 
to exhibit dissolution limited bioavailability, the 
in vivo physiological response is well correlated 
with the in vitro dissolution, resulting eventually 
in good in vitro/in vivo correlations (IVIVC). 
 For accomplishing better solubility or 
dissolution rate of class II drugs use of 
techniques like micronization, co solvents, 
micellar solubilization, solid dispersions and 
complexation has been employed with fruition.70 
a report on bioavailability enhancement using 
self emulsifying formulation by different 
workers is presented in Table 3.71-76 
Conclusions    
Self-emulsifying drug delivery systems are a 
promising approach for the formulation of drug 
compounds with poor aqueous solubility. The 
oral delivery of hydrophobic drugs can be made 
possible by SEDDSs, which have been shown to 
substantially improve oral bioavailability. With 
future development of this technology, SEDDSs 
will continue to enable novel applications in 
drug delivery and solve problems associated 
with the delivery of poorly soluble drugs.  
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